The Decentralized Clinical Operations for Healthcare and Research (D-COHRe) program will initially establish a strong decentralized clinical research capability to support medical countermeasure development and utility.Please see the attached solicitation for full details.
Input from traditional provider groups or healthcare systems that rely primarily on office visits; clinical trial networks/CROS that rely on in-person visits and/or referral from primary care physicians or have defined clinical sites (i.e., centralized models) that have interest in expanding into decentralized care would also be of interest.
This solicitation summary is to notify all potential offerors of a Request for Project Proposals (RPP) issued through the Rapid Response Partnership Vehicle (RRPV) Consortium on behalf of the Biomedical Advanced Research and Development Authority (BARDA), titled, “Enabling Technology – Decentralized Clinical Trial – Home Focus”.The full RPP as well as information on joining the consortium can be accessed through the RRPV website at
Document Type:Grants NoticeFunding Opportunity Number:RFA-DA-25-052Funding Opportunity Title:Tools for decentralized clinical trials for substance use disorder (R43/R44 Clinical Trials Optional)Opportunity Category:DiscretionaryOpportunity Category Explanation: Funding Instrument Type:GrantCategory of Funding Activity:EducationHealthCategory Explanation: Expected Number of Awards: CFDA Number(s):93.279 -- Drug Abuse and Addiction Research ProgramsCost
Through this RFI, BARDA DRIVe is seeking to explore the trend towards healthcare decentralization and to determine whether BARDA’s interests align with commercial capabilities in decentralized healthcare delivery and clinical study models.
ACTR Initiative Summary (More information is available in the Initiative Description): ARPA-H's Advancing Clinical Trial Readiness (ACTR) initiative aims to establish a robust, decentralized clinical trial infrastructure. This initiative will advance, integrate, and extend clinical trial capabilities so that ARPA-H has efficient mechanisms to evaluate new technologies, therapies, and platforms.
Utilizing cutting-edge digital health care and research technologies and approaches, such as digital therapeutics, decentralized and digital clinical trials, and remote devicesfor the engagement, recruitment, and retention of diverse populations.
